EGA
TVRD

Eagle Global Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Eagle Global Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-412
Closed -$92K – 395
2016
Q1 		$92K Buy
+412
New +$123K ﹤0.01% 354

Other funds holding TVRD

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eagle Global Advisors's TVRD Position: Q2 2016 in Review

Eagle Global Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2016, closing a stake of 412 shares — an estimated $92K sold.

Eagle Global Advisors first reported a position in TVRD in Q1 2016 and held it in 1 quarter. The position peaked at $92K in Q1 2016. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

  • Eagle Global Advisors reported no remaining Tvardi Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 412 Tvardi Therapeutics shares in Q2 2016, an estimated $92K.
  • Eagle Global Advisors first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 1 quarter.
  • Eagle Global Advisors's Tvardi Therapeutics position peaked at $92K in Q1 2016.
  • 70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on Eagle Global Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.